Category Press Releases

Cytokinetics Shares New Aficamten Data at ESC Heart Failure 2025 Congress

 Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic…

Read MoreCytokinetics Shares New Aficamten Data at ESC Heart Failure 2025 Congress